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Abstract: Objective: Interstitial lung disease (ILD) frequently complicates systemic sclerosis (SSc). Cyclophosphamide 
(CYC) is a promising immunosuppressive therapy for SSc-related ILD. Our objective was to investigate the effectiveness 
of an intravenous CYC (iv CYC) pulse regime in SSc-related ILD during treatment and thereafter. 
Methods: In a prospective observational study ten consecutive patients with SSc-related ILD were treated with iv CYC in 
a pulse regime lasting from 6 to 24 months. Clinical status, pulmonary functional testing (PFT) and high resolution com-
puted tomography (HRCT) of the chest were evaluated at enrolment and 6, 12 and 24 months thereafter. After treatment 
withdrawal, patients were followed up every 6 months with PFT and chest HRCT to monitor lung disease. 
Results: Clinical improvement was apparent in 8 out of 10 patients. The median values of forced vital capacity (FVC), 
forced expiratory volume in the first second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) as well as 
ground-glass pattern on HRCT did not change significantly after 6, 12 and 24 months of therapy. The follow-up continued 
in 8 out of 10 patients after treatment withdrawal for a median of 26.5 months (range: 12-48 months). The final median 
FVC was 54.5% of predicted value (interquartile range, IQR= 31.6%-94%). Only one patient suffered a FVC deterioration 
greater than 10%, even though less than 160 ml. The final median DLCO was 68% of predicted value (IQR=38.3-83.6%). 
Only 2 patients who developed pulmonary arterial hypertension deteriorated their DLCO values of more than 15%. 
Conclusions: An iv CYC pulse regimen over 24 months may stabilize pulmonary activity in patients with SSc-related ILD 
during the course of treatment and for a median of 26.5 months thereafter. 
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INTRODUCTION 
  The incidence of pulmonary fibrosis in systemic sclerosis 
(SSc) varies from 25% to 90%, depending on the method 
used to identify the interstitial lung disease (ILD) [1]. Pul-
monary fibrosis is the major cause of morbidity and mortal-
ity in SSc patients [2-6]. Therefore, prompt, accurate diagno-
sis of lung involvement is necessary in order to prevent the 
development from the initial alveolitis into the characteristic 
honeycomb pattern. Disease extent is mainly assessed by 
pulmonary function testing (PFT) and high resolution com-
puted tomography (HRCT) [7]. 
  While HRCT is the most sensitive and specific tool to 
identify pulmonary fibrosis in SSc patients, it is not neces-
sarily indicative of the severity of lung impairment [7]. In 
fact PFT is the only widely available means able to identify 
whether the disease is sufficiently severe to justify immedi-
ate therapeutic intervention. 
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  Several studies support the effectiveness of cyclophos-
phamide (CYC) in preventing a decline in lung function and 
delaying death in SSc patients with alveolitis [8-17]. Silver 
et al. [8] first reported that controlling alveolitis with CYC 
may prevent a deterioration of the pulmonary function. In a 
large, retrospective cohort study White et al. showed that 
SSc patients who received CYC therapy for pulmonary alve-
olitis had better lung function outcomes and survival than 
untreated patients [9]. Recently, two double blind, random-
ized, placebo-controlled trials have been reported [10, 11]. 
The first trial, with oral CYC, found a modest but significant 
beneficial effect on lung function and quality of life, but un-
fortunately also serious adverse events in six patients [10]. 
The second trial, with intravenous CYC, demonstrated a 
non-significant trend towards improved forced vital capacity 
(FVC) [11]. Thus, both oral and intravenous (iv) CYC ther-
apy have demonstrated their usefulness in previous studies, 
though the iv route is usually preferred because of its lower 
toxicity [11-21]. 
  The aim of our study was to prospectively analyze the 
effectiveness of an iv CYC pulse regimen on SSc-related 
ILD by PFT and chest HRTC after 6 months, 12 months and 40    The Open Respiratory Medicine Journal, 2008, Volume 2  Simeón-Aznar et al. 
2 years of treatment. A secondary objective was to evaluate 
the outcome of PFT and chest HRTC after withdrawal of iv 
CYC therapy. 
MATERIAL AND METHODS 
 Population: The study was performed at the Vall 
d’Hebron Hospital, a 1,290-bed teaching hospital. SSc pa-
tients were recruited from March 2000 to April 2006 at the 
out-patient clinic for scleroderma Unit of the Internal Medi-
cine Department at our institution. All of them fulfilled the 
American College of Rheumatology criteria for the diagnosis 
of SSc [22]. The only criterion for inclusion in the study was 
chest HRCT compatible with SSc-related ILD and/or FVC  
80% of the predicted value on PFT. Exclusion criteria were: 
1) baseline lymphocytopenia of <1,000; 2) any contraindica-
tion to CYC use; 3) Cytotoxic drugs or biological response 
modifying agents for 12 months before entry; or 4) absence 
of patient’s consent. We evaluated ten consecutive non-
smoking SSc patients who had evidence of ILD. The history, 
duration of lung disease and findings on physical examina-
tion were recorded. Patients were classified as having diffuse 
or limited cutaneous SSc [23]. 
 Study  design: Single-center interventional prospective 
study. Patients were treated following the recommendations 
of Varga J. [24]. 
 Outcomes: the primary outcome was to evaluate the ef-
fectiveness of the iv CYC pulse regime by PFT and chest 
HRCT during the treatment and after drug withdrawal. The 
secondary safety outcome was to estimate the incidence of 
the side-effects of the drug. 
  Protocol for pulmonary evaluation: PFT and chest HRCT 
were evaluated at enrolment and after 6, 12 and 24 months of 
therapy. PFT was performed according to the guidelines of 
the Spanish Thoracic Society [25, 26] using a Compact 
MasterLab equipment (Jaeger Healthcare, Hoechberg, Ger-
many). 
  After discontinuation of the pulse regimen patients were 
followed up with PFT monitoring every 6 months, for a me-
dian period of 26.5 months. PFT included forced spirometry 
and lung transfer capacity studies (DLCO).  Following the 
American Thoracic Society (ATS) recommendations, these 
definitions were applied to evaluate changes from entry to 
final outcome values for FVC, FEV1 and DLCO. Good re-
sponse to therapy was defined as an improvement in FVC or 
FEV1 of 10% or more with an increase of at least 200 ml or 
an improvement of 15% or more in DLCO. Pulmonary func-
tion was considered to have worsened if FVC or FEV1 fell 
by 10% or more with a minimum loss of 200 ml relative to 
the absolute value, or a decrease in DLCO of 15% or more 
[27]. Stability was considered when PFT values were be-
tween these extremes. 
  Chest HRCT scan (Philips Tomoscan AV) was per-
formed using a high-resolution protocol of 1.0-1.5 mm width 
at 15 mm intervals from lung apex to the bases. The sections 
were acquired in supine position at full inspiration. Two con-
sultant chest radiologists who were unaware of the clinical 
information scored all scans independently. Each HRCT 
scan was assessed at 5 levels: origin of the great vessels, 
middle of the aortic arch, main carina, pulmonary venous 
confluence and one cm above the right dome of the dia-
phragm. Each individual section on the HRCT scan was as-
sessed for the presence, pattern, and distribution of intersti-
tial disease. Two distinct patterns of abnormal appearance on 
the HRCT scan were considered: a ground glass pattern, de-
fined as an increased hazy density of the lung parenchyma, 
and a reticular pattern, defined as presence of thickened sep-
tal or subpleural lines, parenchyma subpleural linear bands, 
and honeycombing. The findings were defined in accordance 
with an accepted terminology [28]. The images were scored 
as follows: at each level the overall extent of reticular pattern 
and ground glass opacity was visually estimated to the near-
est 10% according to MacDonald et al. [29]. Overall lung 
involvement was calculated by averaging the percentages for 
each zone. 
 Treatment: A new medical circuit was created for this 
treatment activity, based on the concepts of efficacy, effec-
tiveness and efficiency [30]. Steps for routine administration 
of iv CYC were as follows: a dose of 0.50-0.75 g/m
2 of body 
surface area was administered in an ambulatory manner to all 
SSc-related ILD patients enrolled. Ten patients received iv 
CYC each month for 6 months. In seven patients, the same 
iv CYC dose was continued bimonthly for 6 months and then 
quarterly during the second year, as recently recommended 
[24]. The drug was infused in 500 ml of a 5% glucose solu-
tion for 90 minutes. Two separate iv doses of dexametasone 
4 mg and ondansetron 4 mg were given to minimize adverse 
effects. In order to prevent cystitis, iv mesna was given in 3 
separate doses and patients were advised to increase their 
water intake as much as possible, with a minimum of 1,000 
cc. All patients were also treated with oral prednisone at a 
daily initial dose of 50 mg. After one week prednisone was 
tapered to a daily dose of 5-7.5 mg over 6 weeks, and was 
then maintained throughout the iv CYC pulse treatment. 
  Monitoring of side-effects: Patients were closely moni-
tored for side effects of the drugs. Karch and Lasagna criteria 
were used for side-effect diagnosis [31, 32]. Peripheral blood 
cell count was monitored 15 days after each iv CYC bolus 
with individual dosage adjustments. Thus, if the total leuko-
cyte cell count was below 3x10
9 / L., iv CYC dose was re-
duced by 20% in the next pulse treatment. 
 Statistical  analysis: Statistical analysis was performed 
using SPSS (SPSS Inc., Chicago, IL, USA) version 11.0. 
Measurements were compared between baseline and 6, 12, 
24 months using Wilcoxon´s rank sum test. 
 Informed  consent: Although this treatment is not recom-
mended in the international guidelines, no alternatives to oral 
corticosteroids were available during the study period. 
Therefore, the patients who fulfilled the inclusion criteria 
specified above were systematically offered treatment with 
the iv CYC pulse regimen. Treated patients were asked to 
give written informed consent. Since this is an observational 
study, the Internal Review Board only required patients to 
indicate consent by signing their clinical record. For females 
in fertile status, a report from the gynecologist was required 
to ensure that pregnancy would not occur. 
RESULTS 
  Ten patients (9 women and 1 man) were treated with 
monthly iv CYC pulse. The median age was 49.8 years 
(range: 23-63 years) and the disease duration previous to Intravenous Cyclophosphamide Pulse Therapy  The Open Respiratory Medicine Journal, 2008, Volume 2    41 
treatment was 12.5 years (range: 4-26 years). Seven patients 
had diffuse SSc and three limited SSc. The median duration 
of symptomatic lung disease at entry into the study was 7.6 
years (range: 3-15 years). None of the patients were active 
smokers. Clinical and immunological characteristics are 
shown in Table 1. 
 Clinical  evaluation: All patients received iv CYC pulse 
each month for 6 months. Three patients discontinued pulse 
regimen after 6 months, two because of lymphocytopenia 
before treatment which worsened with its administration, and 
one patient who died from end-stage ILD-related pulmonary 
arterial hypertension (PAH). After this initial pulse regimen, 
seven patients continued bimonthly pulse treatment for 6 
months and then completed a second year of treatment. 
  Pulmonary Function Testing: Spirometry results are 
summarized in Fig. (1) and Table 2. At baseline, seven out of 
10 patients had severely reduced FVC (median: 55.5%) and 
FEV1 (median: 57.3%). Five and three patients respectively 
presented severe or mild reductions in DLCO. In one patient 
DLCO could not be determined because of a very low FVC 
(1.03 litres) and in another DLCO was normal. As a group, 
the median values for FVC, FEV1 and DLCO did not change 
significantly after 6, 12 and 24 months of CYC therapy but 
fulfilled the definition of stable disease. Individually, 7 out 
of 10 patients showed either improvement or stabilization on 
PFT after 6 months of therapy. At 12 months, 5 out of 7 pa-
tients showed improvement or stabilization. At 24 months, 5 
Table 1.  Clinical and Demographic Data of SSc Patients 
 
Patient  Gender
+  Age (Years)  Disease Duration* (Years)  Cutaneous Subset  Lung Disease
++ (Years) ANA
# Title (1: )  Scl-70
& ACA
§ 
1 F  49  15  Diffuse  13  640  Yes  No 
2 F  63  11  Limited  4  2560  Yes  No 
3 F  44  16  Diffuse  12  320  No  No 
4 F  49  26  Limited  8  1280  No  No 
5 M  39  4  Limited  4  80  No  No 
6 F  59  10  Diffuse  5  1280  Yes  No 
7 F  41  8  Diffuse  6  1280  Yes  No 
8 F  47  7  Diffuse  6  640  Yes  No 
9  F  41  16  Diffuse 15 1280  Yes  No 
10 F  23  8  Diffuse  3  160  No  No 
+M: male; F: Female. *from first SSc symptom to beginning of iv CYC pulse therapy. 
++Duration of lung disease. 
#Antinuclear antibodies. 
& Scl-70: antitopoisomerase antibodies. 
§ ACA: anticentromere antibodies. 
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Fig. (1). FVC did not change significantly during follow-up. 42    The Open Respiratory Medicine Journal, 2008, Volume 2  Simeón-Aznar et al. 
out of 7 patients improved or stabilized. 
 Chest  HRCT: Tables 3 and 4 summarize HRCT results. 
At baseline, all patients showed a ground glass appearance 
on chest HRCT, and their median percentage was 18%. After 
6 months of therapy, the overall ground glass pattern did not 
change significantly from baseline but individually there was 
a trend towards a reduction in five out of 10 patients (Table 
3). After 12 months of therapy the ground glass pattern de-
creased in 2 patients and stabilized in two others, and after 
24 months it had fallen in 3 patients and stabilized in one. 
Before the iv CYC pulse regime a reticular pattern was iden-
tified in 7 patients, which did not change significantly after 
therapy. 
 Safety: The treatment was safe and well tolerated. Only 
three patients presented decreased white blood cell count 
after iv CYC boluses and required a dose reduction in subse-
quent pulses. No patient developed episodes of scleroderma 
renal crisis, microscopic hematuria, or infection. 
  Long-term follow-up after discontinuation of the iv CYC 
pulse regimen: Eight out of 10 patients were followed up 
with clinical assessment and PFT every 6 months for a me-
dian of 26.5 months (range: 12-48 months, Table 5). Two 
patients were not followed up: one of them died from pul-
monary arterial hypertension and the remaining patient just 
completed the pulse regime. There was a slight but not sig-
nificant deterioration in DLCO in this treatment-free period. 
Thus the median DLCO at the end of follow-up was 68% of 
predicted value, slightly below the median values at baseline 
(71.7%) and at discontinuation of iv CYC treatment (75%). 
Interestingly, DLCO deteriorated more than 15% after cessa-
tion of iv CYC in only two patients (patients 2 and 4), who 
developed PAH during this period. 
  There was no significant change in the median value of 
FVC at the end of follow-up (54.5%; IQR= 31.6-94%) when 
compared with the baseline FVC (55.5%; IQR= 32-92.7%) 
and at cessation of iv CYC (56.7%; IQR= 31.6-82%). There-
fore the median deterioration in FVC was only -1.15 % 
(range: -12.3% to +11.5%). 
Table 2.  Individual and Median Scores of Pulmonary Function Testing 
 
FEV1 (%)  FVC (%) 
Patient 
Time 0  6 Months   12 Months   24 Months  Time 0  6 Months  12 Months  24 Months 
1 56.6  61.8  -  -  58.5  55.4  -  - 
2 56.8  84.3  72  73.5  55  84.9  61.7  71.2 
3 57.9  57  60  63.7  50.8  58  60  58.5 
4 49.4  53.1  -  -  41.6  44.6  -  - 
5  89.3 71.7 80.2 69.6  77.7  58.8  65.6  54.9 
6 103  90.7  -  -  92.7  82  -  - 
7  87.9  66.2  67 71.9  85.2 54.8  58 62.6 
8 36  39.7  35.8  36.8  34  34  34.6  32.7 
9 41  41.4  42.7  42.7  32  32.8  31.6  31.6 
10  68  79.6  72.3   80.4  56  68.1  61.3   73.7 
Median  57.3  64 67 69.6  55.5 56.7  60 58.5 
Table 3.  Percentages of Ground Glass Pattern in Serial Pulmonary HRCT 
 
 Patients  Baseline (%)  at 6 Months (%)  at 12 Months (%)  at 24 Months (%) 
1 32  30  -  - 
2 4  6  8  5 
3 14  12  14  14 
4 32  28  -  - 
5 18  28  24  24 
6 8  8  -  - 
7 26  34  34  30 
8 14  14  14  12 
9 18  10  10  10 
10 32  14  24  10 
Median 18  14  14  12 Intravenous Cyclophosphamide Pulse Therapy  The Open Respiratory Medicine Journal, 2008, Volume 2    43 
DISCUSSION 
  SSc-related ILD outcome is usually poor when no suc-
cessful immunosuppressive treatment is administered, and it 
is associated with increased morbidity and mortality [2, 3, 4]. 
The optimal treatment for SSc-related ILD patients and the 
ideal test for evaluating treatment response remain uncertain. 
  PFT and HRCT were chosen in the present study for the 
pulmonary evaluation because they are widely considered 
pivotal in the assessment of ILD. In most studies performed 
to date lung volumes and DLCO were monitored but results 
were heterogeneous because of few used the ATS criteria. 
The notable improvement in DLCO observed by Giacomelli 
et al. [15] was not associated with a significant rise in FVC 
value, a finding that may reflect the fact that the initial FVC 
parameter was within the normal range in 17 out of 23 cases. 
In our study, which applied the ATS criteria, the median 
values for FVC, FEV1 and DLCO after 6, 12 and 24 months 
of iv CYC therapy remained stable. 
  HRCT also has limitations, because the lack of a single 
validated scoring system to evaluate ILD makes it difficult to 
quantify the radiological changes reported by different stud-
ies. We used HRCT changes as an endpoint because recent 
data have suggested that it is a good method to determine the 
morphological extent of alveolitis and fibrosis [29]. Moreo-
ver, the literature shows a fairly consistent pattern of positive 
effects of iv CYC therapy in SSc patients according to 
HRCT findings: it has been reported that this treatment in-
duces regression of ground glass opacities on HRCT [11, 12, 
14], particularly in patients with very early lung disease [16], 
although sometimes the regression does not reach statistical 
significance [11, 15, 20]. It should be kept in mind that the 
small number of patients enrolled in single-center studies 
might limit the probability of detecting statistically signifi-
cant improvement in HCRT findings. Taken together, these 
observations suggest that iv CYC may have a favorable ef-
fect on ILD parameters other than PFT. 
  In our study, there was no statistically significant change 
in ground glass percentage overall, although individually it 
fell in 5 out of 10 patients after 6 months of treatment. This 
probably reflects the favorable response of alveolitis to im-
munosuppressive therapy, before fibrosis is well established. 
No changes were observed when a reticular pattern was pre-
sent. 
Table 4.  Percentages of Reticular Pattern in Pulmonary HRCT 
 
Patient  Baseline (%)  6 Months (%)  12 Months (%)  24 Months (%) 
1 28  32  -  - 
2 0  0  2  0 
3 2  2  2  2 
4 20  20  -  - 
5 0  10  10  10 
6 0  0  -  - 
7 2  4  2  2 
8 8  8  8  8 
9 18  22  22  22 
10 12  12  14  10 
Median 5  9  10  8 
Table 5.  Long Term Results After iv CYC Withdrawal 
 
Patient  Duration of follow Up 
(Months) 
Final DLCO
+ (%)  % Change from DLCO at the  
End of Treatment 
Final FVC
* (%)  % Change from FVC at the End of  
Treatment 
2 25  68  -24  54.5  -9.8 
3 28  72.8  -2.1  54.6  -6.7 
4 48  38.3  -44  39.9  -12.3 
5 12  52  -13  57  +2.1 
6 32  83.6  +1.6  94  +11.5 
7 27  60.8  -3.1  66  +1.5 
8 26  83  -1  36.8  +10.8 
9 14  -  -  31.6  -3.8 
Median 26.5  68  -3.1  54.5  -1.15 
 +Percentage of predicted DLCO value. 
*Percentage of predicted FVC value. 44    The Open Respiratory Medicine Journal, 2008, Volume 2  Simeón-Aznar et al. 
  The most convincing data comes from a recent multicen-
ter, placebo-controlled trial of oral CYC in patients with 
well-defined, symptomatic SSc-related alveolitis, carried out 
by the Scleroderma Lung Study Research Group [10]. This 
report showed modest but statistically significant improve-
ments in lung function and symptoms over one year of fol-
low-up and adds good circumstantial evidence that oral CYC 
is effective. Unfortunately, the risk of cancer, gonadal failure 
and other adverse events increases with cumulative dose, 
especially when the drug is administered daily. Recently, the 
results of an iv CYC showed a non-significant lung function 
response to active therapy probably because the sample size 
was limited, but tolerance and compliance were acceptable 
[11]. The initial pilot studies [12, 13] and the eight studies 
published later including a total of 121 patients [14-21] 
showed consistent evidence of the effectiveness of the iv 
CYC pulse regimen. 
  Our prospective study shows that the iv CYC pulse regi-
men may stabilize ILD activity in patients with SSc both 
while in treatment and for a median of 26.5 months thereaf-
ter. The results of the long-term follow-up were relatively 
favorable: only two patients experienced a significant dete-
rioration in DLCO, in both cases due to PAH. In the study by 
Griffiths et al. [16], PFT remained stable over 6 months after 
iv CYC withdrawal but DLCO deteriorated significantly in 
the majority of patients in further follow-up. The better re-
sults obtained in the present study were probably related to 
the iv CYC pulse regimen. Maintenance pulse therapy for 12 
months may achieve further improvement [12, 14]. Some 
years ago, experts in SSc-related ILD [24] recommended that 
if a successful clinical and functional response is observed 
after a six-monthly iv CYC regimen, the interval should be 
extended bimonthly over 6 months and then quarterly over 
the second year. To our knowledge, the present study is the 
only one to have applied this regimen to date and 7 out of 10 
of our patients experienced an improvement or stabilization 
by the end of treatment. Moreover, the absence of any rele-
vant  related adverse events demonstrated that this long iv 
CYC pulse regime was safe. 
CONCLUSION 
  In conclusion, although our study shares the limitations 
of other studies in the literature, it suggests that an iv CYC 
pulse regime over 24 months may stabilize or improve PFT 
and chest HRCT, with good tolerance in at least some pa-
tients with SSc-related ILD. Our findings are consistent with 
the conclusions of two recently published prospective studies 
[10, 11]. 
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